波普瑞韦

Description

Boceprevir · CAS 394730-60-0 · C27H45N5O5. UNII 89BT58KELH.

Identification

CAS Registry Number	394730-60-0
PubChem CID	10324367
Molecular formula	C27H45N5O5
IUPAC name	(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
UNII (FDA)	89BT58KELH

Computed Descriptors

Molecular Weight	519.7
XLogP3	3.1
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	10
Exact Mass	519.34206955
Monoisotopic Mass	519.34206955
Topological Polar Surface Area	151
Heavy Atom Count	37
Formal Charge	0

Physical description & handling notes

• White to off-white amorphous powder
• Slightly soluble in water
• Freely soluble in methanol, ethanol, and isopropanol
• Boceprevir is classified as a direct-acting antiviral (DAA) and prevents viral replication in HCV genotype 1.
• VICTRELIS 200 mg Capsules, red-colored cap with the Merck logo printed in yellow ink, and a yellow-colored body with "314" printed in red ink.

GHS Hazard Classification

Reported hazard statements	H302 (92.9%), H361 (92.9%)

Documented Uses

• Manufactured as an approximately equal mixture of two diasteromers.
• Boceprevir, when used in combination with [DB00811], [DB00008], and [DB00022] is indicated for use in the treatment of chronic HCV genotype 1 infection in adults.
• Boceprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor that was used in combination with peginterferon and ribavirin in the treatment of chronic hepatitis C, genotype 1. Initially approved for use in 2012, it was withdrawn in 2015 because of the availability of more effective and better tolerated all oral regimens of direct acting antiviral agents. Boceprevir was not linked to instances of acute liver injury during therapy but, when combined with peginterferon and ribavirin, was associated
• Breast Feeding; Lactation; Milk, Human; Antiviral Agents; Protease Inhibitors
• Boceprevir is indicated for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy. /Included in US product label/
• Boceprevir must not be used as monotherapy and should only be used in combination with peginterferon alfa and ribavirin. /Included in US product label/

Synonyms

Boceprevir; 394730-60-0; Victrelis; SCH 503034; EBP 520; SCH-503034; SCH503034; EBP-520; 89BT58KELH; CHEBI:68621; boceprevirum; RefChem:56897; J05AP03; MFCD22208555; SCH 50304; Boceprevir(>90%)

Frequently Asked Questions

What are the CAS number and molecular formula of Boceprevir?

CAS 394730-60-0; molecular formula C27H45N5O5; molecular weight — g/mol.

What other names is Boceprevir known by?

Boceprevir, 394730-60-0, Victrelis, SCH 503034, EBP 520, SCH-503034.

Is Boceprevir classified as hazardous?

Hazard statements reported: H302, H361.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.